Core Viewpoint - Akebia Therapeutics (AKBA) is anticipated to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended March 2025, with a consensus outlook suggesting a quarterly loss of $0.03 per share, reflecting a 66.7% improvement from the previous year, and revenues expected to reach $45.21 million, a 38.6% increase from the same quarter last year [1][3]. Earnings Expectations - The stock price may rise if the actual earnings exceed expectations in the upcoming report, while a miss could lead to a decline in stock value [2]. - The consensus EPS estimate has been revised 30% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a positive Earnings ESP of +45.46% for Akebia Therapeutics, suggesting a strong likelihood of beating the consensus EPS estimate [11]. - The company currently holds a Zacks Rank of 3, which, when combined with the positive Earnings ESP, indicates a favorable outlook for the upcoming earnings report [11]. Historical Performance - In the last reported quarter, Akebia Therapeutics was expected to post a loss of $0.08 per share but actually reported a loss of $0.10, resulting in a surprise of -25% [12]. - Over the past four quarters, the company has only surpassed consensus EPS estimates once [13]. Industry Comparison - Another player in the Zacks Medical - Drugs industry, Heron Therapeutics (HRTX), is expected to report a loss of $0.01 per share for the same quarter, reflecting a year-over-year change of +50%, with revenues projected at $37.08 million, a 7% increase from the previous year [17]. - Heron Therapeutics has seen a 50% upward revision in its consensus EPS estimate over the last 30 days and holds an Earnings ESP of 100.00%, indicating a strong likelihood of beating the consensus EPS estimate [18].

Core Viewpoint - Akebia Therapeutics, Inc. is set to release its financial results for Q1 2025 on May 8, 2025, before market opening [1][2] Group 1: Financial Results Announcement - The financial results for the first quarter ended March 31, 2025, will be announced on May 8, 2025 [1] - A conference call will be held on the same day at 8:00 a.m. EDT to discuss the financial results and recent business highlights [2] Group 2: Conference Call Details - Participants can register for the conference call through a provided link to receive dial-in details [2] - It is recommended to join the call 15 minutes early to ensure timely connection [2] - A live webcast of the conference call will be available on Akebia's Investors section of their website [3] Group 3: Company Overview - Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease [4] - The company was founded in 2007 and is headquartered in Cambridge, Massachusetts [4]

Group 1 - The core point of the news is the performance of the Zhongyin Innovation Medical Mixed A fund, which has shown significant growth in its net value and returns over various time frames [1] - As of April 21, 2025, the latest net value of Zhongyin Innovation Medical Mixed A is 1.6127 yuan, reflecting a growth of 2.27% [1] - The fund's one-month return is 14.21%, ranking 9th out of 4672 similar funds; the three-month return is 36.72%, ranking 18th out of 4599; and the year-to-date return is 34.02%, ranking 36th out of 4590 [1] Group 2 - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.60%, with significant positions in companies such as Heng Rui Pharmaceutical (9.81%), Innovent Biologics (8.55%), and others [1] - The fund was established on November 13, 2019, and as of December 31, 2024, it has a total scale of 2.02 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry since 2022 [2]

Core Viewpoint - The recent performance of the Zhongyin Innovation Medical Mixed A fund shows a decline in net value but strong returns over various time frames, indicating potential resilience in the healthcare investment sector [1]. Fund Performance Summary - The latest net value of Zhongyin Innovation Medical Mixed A is 1.5786 yuan, down by 2.81% - The fund's one-month return is 13.30%, ranking 7 out of 4623 in its category - The three-month return stands at 38.74%, ranking 14 out of 4566 - Year-to-date return is 31.19%, ranking 24 out of 4559 [1]. Holdings Summary - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.60%, with the following key positions: - Heng Rui Pharmaceutical: 9.81% - Xinda Bio: 8.55% - Huaneng Pharmaceutical: 8.41% - Kangfang Biotech: 8.35% - Kangnuo Ya-B: 8.32% - Kelun Botai: 7.87% - BeiGene-U: 6.24% - Rongchang Bio: 5.96% - Hansoh Pharmaceutical: 3.98% - Xin Nuo Wei: 3.11% [1]. Fund Manager Background - Zheng Ning, the fund manager, has a master's degree and extensive experience in the investment sector, having previously worked at Taikang Asset Management and Zhonggeng Fund Management - Zheng joined Zhongyin Fund Management in 2022 and has managed multiple funds since then, including the Zhongyin Innovation Medical Mixed Fund [2].

Company Overview - Akebia Therapeutics, Inc. (AKBA) is currently positioned as an intriguing investment choice within the Medical - Drugs sector due to solid earnings estimate revision activity [1][3] - The company has seen a positive shift in earnings estimates, indicating a more bullish outlook from analysts regarding its short and long-term prospects [3] Industry Context - The Medical - Drugs industry has a Zacks Industry Rank of 83 out of more than 250 industries, suggesting it is well-positioned compared to other segments [2] - A rising trend in the industry can positively impact securities across the board, benefiting companies like Akebia Therapeutics [2] Earnings Estimates - Over the past month, current quarter estimates for Akebia have improved from a loss of 6 cents per share to a loss of 3 cents per share [4] - Current year estimates have also seen an increase, moving from a loss of 14 cents per share to a loss of 13 cents per share [4] - The company holds a Zacks Rank 3 (Hold), which is considered a favorable signal for potential investors [4] Investment Consideration - Given the strong industry performance and positive estimate revisions, Akebia Therapeutics is recommended as a decent pick for investors looking for opportunities in a robust industry segment [5]

Company Overview - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [3]. Upcoming Event - Akebia will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) in Boston, MA from April 10-13, 2025 [1]. - The company will have posters displayed during the Exhibit Hall hours at NKF SCM25 [1]. Research Presentation - On April 10, 2025, Dr. Wolfgang Winkelmayer will present a poster titled "Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD" during the Oral Poster Presentation: Research 3 session [2]. - Akebia will also have a booth (1121) at the NKF SCM25 for attendees to visit [2].

Company Overview - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [5]. Offering Details - Akebia announced a public offering of 25,000,000 shares of common stock at a price of $2.00 per share, aiming to raise gross proceeds of $50.0 million before expenses [1]. - The underwriters have a 30-day option to purchase up to 3,750,000 additional shares at the public offering price [1]. - The offering is expected to close on March 21, 2025, pending customary closing conditions [1]. Underwriters - Leerink Partners and Piper Sandler & Co. are serving as joint bookrunning managers for the offering, with BTIG, LLC as the lead manager and H.C. Wainwright & Co. as co-manager [2]. Regulatory Compliance - The shares are being offered under a shelf registration statement filed with the SEC on September 3, 2024, which was declared effective on September 12, 2024 [2]. - A preliminary prospectus supplement has been filed with the SEC, and a final prospectus will also be filed [3]. Contact Information - For inquiries regarding the offering, contact details for Leerink Partners and Piper Sandler & Co. are provided [3].

Core Viewpoint - Akebia Therapeutics, Inc. has initiated an underwritten public offering of its common stock, with the potential for underwriters to purchase an additional 15% of shares sold in the offering [1][2]. Group 1: Offering Details - The offering is being conducted under a shelf registration statement filed with the SEC on September 3, 2024, and declared effective on September 12, 2024 [2]. - A preliminary prospectus supplement detailing the terms of the offering is expected to be filed with the SEC [3]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the final terms [1][6]. Group 2: Company Overview - Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [5].

Financial Data and Key Metrics Changes - Total revenues for Q4 2024 were $46.5 million, down from $56.2 million in Q4 2023, and for the full year 2024, revenues were $160.2 million compared to $194.6 million in 2023 [38] - Net product revenues from Auryxia were $44.4 million in Q4 2024, down from $53.2 million in Q4 2023, and for the full year, they were $152.2 million compared to $170.3 million in 2023 [38] - The net loss for Q4 2024 was $22.8 million, compared to a net income of $0.6 million in Q4 2023, and the full year net loss was $69.4 million compared to $51.9 million in 2023 [41][42] Business Line Data and Key Metrics Changes - The launch of Vafseo is in its early stages, with expected net product revenue of $10 million to $11 million for Q1 2025, which is ahead of analyst estimates [10][21] - Auryxia's sales decline was primarily due to a reduction in volume, partially offset by price increases and effective contracting strategies [38] Market Data and Key Metrics Changes - The demand for Vafseo is strong, with over 500 physicians prescribing it by the end of February, averaging about eight prescriptions each [33][76] - Approximately 15% of prescriptions for Vafseo were written for payers other than Medicare fee-for-service, indicating early success in Medicare Advantage coverage [36][86] Company Strategy and Development Direction - The company aims to make Vafseo the standard-of-care for patients with anemia due to chronic kidney disease, focusing on both dialysis and non-dialysis patient populations [10][17] - The strategy includes securing contracts with dialysis organizations and building prescriber demand, with a focus on small to medium-sized dialysis organizations initially [12][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early traction of Vafseo and the potential for it to become a standard treatment option [10][38] - The company is preparing for a Phase 3 clinical trial (VALOR) for non-dialysis patients, with plans to initiate the study in the second half of 2025 [18][96] Other Important Information - The company raised $18.4 million in net proceeds from sales under its ATM facility and drew down $9.3 million from its BlackRock Credit Agreement, strengthening its financial position [44] - Cash and cash equivalents as of December 31, 2024, were $51.9 million, expected to fund operations for at least two years [43] Q&A Session Summary Question: Does Q1 Vafseo revenue include any stocking or inventory build? - Management confirmed that there will be a little bit of inventory included in the revenue guidance, with inventory expected to stay in the two to four week range [48] Question: What are the dose frequency trends for in-center dialysis patients? - Most patients are currently on a daily dosing protocol, with some smaller centers starting TIW dosing [49] Question: How is protocolization gaining uptake at large-scale dialysis organizations? - Management noted that operationalizing protocols is taking longer than expected, but there is a desire from physicians to write prescriptions [52][53] Question: Can you expand on the recent backlog in Auryxia? - The backlog was for all phosphate binders and Vafseo due to the transition to specialty pharmacies, but it has subsided significantly [61] Question: What is the timing for the VALOR study regulatory interaction? - The focus is on study design, and management is looking to initiate the VALOR study as quickly as possible [66][68] Question: What are the launch metrics planned for disclosure? - Over 500 physicians have prescribed Vafseo, with an average of eight prescriptions per prescriber, indicating good breadth and depth of prescribing [76] Question: What is the current gross to net outlook? - Management did not provide specific gross to net figures but indicated that the average prescriptions are for the starting dose, with discounts expected to grow as volumes increase [90][91]

Financial Data and Key Metrics Changes - Total revenues for Q4 2024 were $46.5 million, down from $56.2 million in Q4 2023, and for the full year 2024, revenues were $160.2 million compared to $194.6 million in 2023 [38] - Net product revenues from Auryxia were $44.4 million in Q4 2024, down from $53.2 million in Q4 2023, and for the full year, they were $152.2 million compared to $170.3 million in 2023 [38] - The net loss for Q4 2024 was $22.8 million, compared to a net income of $0.6 million in Q4 2023, and the full year net loss was $69.4 million compared to $51.9 million in 2023 [41][42] Business Line Data and Key Metrics Changes - The launch of Vafseo is in its early stages, with expected net product revenue of $10 million to $11 million for Q1 2025, which is ahead of analyst estimates [10][21] - Auryxia's revenues decreased primarily due to a reduction in volume, partially offset by price increases and execution of contracting strategies [38] Market Data and Key Metrics Changes - The demand for Vafseo is strong, with over 500 physicians prescribing it by the end of February, averaging about eight prescriptions each [33][76] - Approximately 15% of prescriptions in February were written for payers other than Medicare fee-for-service, indicating early Medicare Advantage coverage [36][86] Company Strategy and Development Direction - The company aims to make Vafseo the standard-of-care for patients with anemia due to chronic kidney disease, focusing on both dialysis and non-dialysis patient populations [10][17] - The strategy includes securing contracts with dialysis organizations and building prescriber demand, with a focus on small to medium dialysis organizations initially [12][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early traction of Vafseo and the potential for it to become a standard treatment option [10][38] - The company is preparing for a Phase 3 clinical trial (VALOR) for non-dialysis patients, with plans to initiate the study in the second half of the year [18][96] Other Important Information - The company raised $18.4 million in net proceeds from sales under its ATM facility and drew down $9.3 million from its BlackRock Credit Agreement, strengthening its financial position [44] - Cash and cash equivalents as of December 31, 2024, were $51.9 million, expected to be sufficient to fund operations for at least two years [43] Q&A Session Summary Question: Does Q1 Vafseo revenue include any stocking or inventory build? - Management confirmed that there will be a little bit of inventory included in the revenue guidance, with inventory expected to stay in the two to four week range [48] Question: What are the dose frequency trends for in-center dialysis patients? - Most patients are currently on a daily dosing protocol, with some smaller centers starting protocols with less frequent dosing [49] Question: How is protocolization gaining uptake at large-scale dialysis organizations? - Management noted that operationalizing protocols takes time, and while some larger organizations have written protocols, implementation is slower than desired [52] Question: Can you expand on the recent backlog in Auryxia? - The backlog was for all phosphate binders and Vafseo due to the transition to specialty pharmacies, which initially lacked capacity [60] Question: What is the timing for the VALOR study regulatory interaction? - The focus is on study design, and management is looking to initiate discussions with the FDA to expedite the process [68][96]